8-K Announcements
6Material company update
Mar 12, 2026·SEC
Material company update
Mar 10, 2026·SEC
Material company update
Dec 5, 2025·SEC
Capricor Therapeutics, Inc.(CAPR)Earnings, Financials & Key Ratios
CAPR•NASDAQ
$33.94
$1.55B mkt cap·Price updated May 7, 2026
AboutCapricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.Show more
- Revenue$22M-11.5%
- EBITDA-$41M-78.8%
- Net Income-$40M-81.6%
- EPS (Diluted)-1.15-38.6%
- Gross Margin-124.37%-177.9%
- EBITDA Margin-184.73%-102.1%
- Operating Margin-191.13%-99.9%
- Net Margin-181.71%-105.3%
- ROE-48.16%+62.8%
- ROIC-43.8%+81.9%
- Debt/Equity0.01-89.9%
CAPR Key Insights
Capricor Therapeutics, Inc. (CAPR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 97 (top 3%)
- ✓Strong 5Y sales CAGR of 85.8%
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 31.5% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CAPR Price & Volume
Capricor Therapeutics, Inc. (CAPR) stock price & volume — 10-year historical chart
Loading chart...
CAPR Growth Metrics
Capricor Therapeutics, Inc. (CAPR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years18.25%
5 Years85.83%
3 Years349.69%
TTM-52.08%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-140.35%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-69.03%
Return on Capital
10 Years-96.25%
5 Years-71.36%
3 Years-76.86%
Last Year-48.12%
CAPR Recent Earnings
Capricor Therapeutics, Inc. (CAPR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 5/12 qtrs (63%)
Q2 2026Latest
Mar 12, 2026EPS
$0.62
Est $0.51
-21.6%
Revenue
—
Est $525,000
Q4 2025
Nov 10, 2025EPS
$0.54
Est $0.54
+0.0%
Revenue
—
Est $600,000
Q3 2025
Aug 11, 2025EPS
$0.57
Est $0.48
-18.8%
Revenue
—
Est $480,000
Q2 2025
May 13, 2025EPS
$0.53
Est $0.33
-60.6%
Revenue
—
Est $3M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 12, 2026 | $0.62vs $0.51-21.6% | —vs $525,000 |
| Q4 2025 | Nov 10, 2025 | $0.54vs $0.54+0.0% | —vs $600,000 |
| Q3 2025 | Aug 11, 2025 | $0.57vs $0.48-18.8% | —vs $480,000 |
| Q2 2025 | May 13, 2025 | $0.53vs $0.33-60.6% | —vs $3M |
Based on last 12 quarters of dataView full earnings history →
CAPR Peer Comparison
Capricor Therapeutics, Inc. (CAPR) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SRPT | 2.18B | 20.80 | -2.92 | 15.58% | 2.98% | 4.89% | 0.91 | |
 CRSP | 5.06B | 52.42 | -8.10 | -89.97% | -138.57% | -30.88% | 0.21 | |
 EXEL | 11.74B | 46.21 | 16.62 | 6.98% | 35.08% | 40.21% | 0.08 | |
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 RARE | 2.57B | 26.13 | -4.48 | 20.13% | -91.03% | -6.08% | ||
 EDIT | 296.54M | 3.03 | -1.68 | -100% | -5.23% | 0.66 | ||
 NTLA | 1.62B | 13.71 | -3.60 | 16.92% | -6.1% | -56.63% | 0.14 | |
 BEAM | 3.23B | 31.47 | -38.85 | 120.01% | -49.17% | -5.89% | 0.24 |
Compare CAPR vs Peers
Capricor Therapeutics, Inc. (CAPR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CAPR Income Statement
Capricor Therapeutics, Inc. (CAPR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 3.19M | 2.67M | 1.67M | 1.01M | 310.25K | 244.9K | 2.55M | 25.18M | 22.27M | 11.13M |
| Revenue Growth % | -15.52% | -16.43% | -37.32% | -39.85% | -69.13% | -21.06% | 941.85% | 886.81% | -11.55% | -52.08% |
| Cost of Goods Sold | 0 | 0 | 0 | 5.14M | 0 | 0 | 21.82M | 36.45M | 49.97M | 75.88M |
| COGS % of Revenue | - | - | - | 511.61% | - | - | 855.07% | 144.76% | 224.37% | - |
| Gross Profit | -12.04M▲ 0% | 2.67M▲ 122.1% | 1.67M▼ 37.3% | -4.14M▼ 347.6% | 310.25K▲ 107.5% | 244.9K▼ 21.1% | -19.27M▼ 7966.7% | -11.27M▲ 41.5% | -27.7M▼ 145.8% | -64.75M▲ 0% |
| Gross Margin % | -377.52% | 100% | 100% | -411.61% | 100% | 100% | -755.07% | -44.76% | -124.37% | -581.7% |
| Gross Profit Growth % | -46.15% | 122.14% | -37.32% | -347.56% | 107.5% | -21.06% | -7966.74% | 41.5% | -145.77% | - |
| Operating Expenses | 4.93M | 4.76M | 17M | 3.6M | 14M | 21.18M | 10.43M | 12.81M | 14.87M | 21.94M |
| OpEx % of Revenue | 154.64% | 178.66% | 1017.24% | 357.91% | 4512.56% | 8649.86% | 408.86% | 50.87% | 66.76% | - |
| Selling, General & Admin | 4.93M | 4.76M | 4.93M | 3.6M | 5.54M | 7.61M | 10.43M | 12.81M | 14.87M | 21.94M |
| SG&A % of Revenue | 154.64% | 178.66% | 295.15% | 357.91% | 1786.69% | 3108.35% | 408.86% | 50.87% | 66.76% | - |
| Research & Development | 16.04M | 10.77M | 12.07M | 5.14M | 8.46M | 13.57M | 21.82M | 36.45M | 49.97M | 75.88M |
| R&D % of Revenue | 502.88% | 403.83% | 722.14% | 511.61% | 2725.87% | 5541.51% | 855.07% | 144.76% | 224.37% | - |
| Other Operating Expenses | -809K | -10.77M | 0 | -5.14M | 0 | 0 | -21.82M | -36.45M | -49.97M | -4M |
| Operating Income | -16.98M▲ 0% | -12.86M▲ 24.2% | -15.33M▼ 19.2% | -7.73M▲ 49.5% | -13.69M▼ 77.0% | -20.94M▼ 52.9% | -29.7M▼ 41.8% | -24.08M▲ 18.9% | -42.56M▼ 76.8% | -86.68M▲ 0% |
| Operating Margin % | -532.19% | -482.45% | -917.24% | -769.52% | -4412.56% | -8549.86% | -1163.93% | -95.63% | -191.13% | -778.8% |
| Operating Income Growth % | -34.61% | 24.24% | -19.16% | 49.54% | -77.01% | -52.95% | -41.83% | 18.92% | -76.78% | - |
| EBITDA | -16.85M | -12.72M | -15.17M | -7.56M | -13.55M | -20.69M | -29.16M | -23.01M | -41.14M | -84.92M |
| EBITDA Margin % | -528.25% | -477.04% | -907.8% | -752.41% | -4366.18% | -8449.54% | -1143.04% | -91.39% | -184.73% | -762.96% |
| EBITDA Growth % | -34.8% | 24.53% | -19.28% | 50.15% | -79.14% | -52.76% | -40.94% | 21.11% | -78.8% | -144.09% |
| D&A (Non-Cash Add-back) | 125.72K | 144.17K | 157.65K | 171.96K | 143.89K | 245.7K | 533.13K | 1.07M | 1.43M | 1.76M |
| EBIT | -16.98M | 2.83M | -15.33M | -7.73M | -13.69M | -20.94M | -29.7M | -24.08M | -42.56M | -84.97M |
| Net Interest Income | -344.67K | -398.81K | 0 | 0 | 0 | 0 | 521.53K | 1.73M | 2.2M | 4.92M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 521.53K | 1.73M | 2.2M | 4.92M |
| Interest Expense | 344.67K | 398.81K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -1.83M | 15.29M | 135.99K | 92.07K | 32.94K | 915.92K | 677.85K | 1.79M | 2.1M | 4.69M |
| Pretax Income | -18.81M▲ 0% | 2.43M▲ 112.9% | -15.19M▼ 724.9% | -7.64M▲ 49.7% | -13.66M▼ 78.7% | -20.02M▼ 46.6% | -29.02M▼ 44.9% | -22.29M▲ 23.2% | -40.47M▼ 81.6% | -81.99M▲ 0% |
| Pretax Margin % | -589.56% | 91.19% | -909.1% | -760.36% | -4401.94% | -8175.86% | -1137.37% | -88.52% | -181.71% | -736.62% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -18.81M▲ 0% | 2.43M▲ 112.9% | -15.19M▼ 724.9% | -7.64M▲ 49.7% | -13.66M▼ 78.7% | -20.02M▼ 46.6% | -29.02M▼ 44.9% | -22.29M▲ 23.2% | -40.47M▼ 81.6% | -81.99M▲ 0% |
| Net Margin % | -589.56% | 91.19% | -909.1% | -760.36% | -4401.94% | -8175.86% | -1137.37% | -88.52% | -181.71% | -736.62% |
| Net Income Growth % | -46.28% | 112.93% | -724.89% | 49.7% | -78.71% | -46.61% | -44.93% | 23.2% | -81.57% | -140.35% |
| Net Income (Continuing) | -18.81M | 2.43M | -15.19M | -7.64M | -13.66M | -20.02M | -29.02M | -22.29M | -40.47M | -81.99M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -10.14▲ 0% | 0.90▲ 108.9% | -5.17▼ 674.4% | -2.06▲ 60.2% | -0.88▲ 57.3% | -0.87▲ 1.1% | -1.18▼ 35.6% | -0.83▲ 29.7% | -1.15▼ 38.6% | -1.79▲ 0% |
| EPS Growth % | -25.34% | 108.88% | -674.44% | 60.15% | 57.28% | 1.14% | -35.63% | 29.66% | -38.55% | -69.03% |
| EPS (Basic) | -10.14 | 1.00 | -5.17 | -2.06 | -0.88 | -0.87 | -1.18 | -0.83 | -1.15 | - |
| Diluted Shares Outstanding | 1.85M | 2.68M | 2.94M | 3.71M | 15.57M | 23.09M | 24.55M | 26.78M | 35.22M | 45.72M |
| Basic Shares Outstanding | 1.85M | 2.32M | 2.94M | 3.71M | 15.57M | 23.09M | 24.55M | 26.78M | 35.22M | 45.72M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CAPR Balance Sheet
Capricor Therapeutics, Inc. (CAPR) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 18.11M | 15.71M | 8.47M | 10.54M | 33.68M | 36.44M | 42.89M | 50.86M | 163.39M | 100.95M |
| Cash & Short-Term Investments | 16.19M | 14.12M | 7.26M | 9.89M | 32.67M | 34.89M | 41.42M | 39.49M | 151.52M | 98.57M |
| Cash Only | 3.2M | 6.14M | 4.26M | 3.9M | 32.67M | 34.89M | 9.6M | 14.69M | 11.29M | 19.51M |
| Short-Term Investments | 12.99M | 7.98M | 3M | 5.99M | 0 | 0 | 31.82M | 24.79M | 140.23M | 79.06M |
| Accounts Receivable | 223.34K | 344.57K | 204.87K | 87.97K | 56K | 391.75K | 547.58K | 10.37M | 10.37M | 59.17K |
| Days Sales Outstanding | 25.55 | 47.18 | 44.75 | 31.95 | 65.88 | 583.87 | 78.33 | 150.36 | 169.93 | 86.47 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 1.35M | 742K | 285.83K | 0 | -56K | 0 | 919.89K | 0 | 0 | 2.33M |
| Total Non-Current Assets | 639.01K | 561.11K | 775.77K | 568.91K | 941.71K | 4.89M | 7.21M | 7.88M | 7.1M | 25.49M |
| Property, Plant & Equipment | 435.34K | 372.1K | 574.21K | 442.81K | 850.85K | 4.62M | 6.94M | 7.61M | 6.87M | 25M |
| Fixed Asset Turnover | 7.33x | 7.16x | 2.91x | 2.27x | 0.36x | 0.05x | 0.37x | 3.31x | 3.24x | 0.93x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 142.25K | 93.05K | 204.87K | 6.5K | 2.17K | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 61.43K | 95.97K | 151.79K | 119.61K | 88.7K | 275.72K | 268.17K | 268.17K | 221.7K | 1.47M |
| Total Assets | 18.75M▲ 0% | 16.27M▼ 13.2% | 9.25M▼ 43.2% | 11.11M▲ 20.2% | 34.62M▲ 211.5% | 41.33M▲ 19.4% | 50.09M▲ 21.2% | 58.73M▲ 17.2% | 170.48M▲ 190.3% | 126.44M▲ 0% |
| Asset Turnover | 0.17x | 0.16x | 0.18x | 0.09x | 0.01x | 0.01x | 0.05x | 0.43x | 0.13x | 0.08x |
| Asset Growth % | 16.66% | -13.19% | -43.18% | 20.19% | 211.5% | 19.39% | 21.21% | 17.25% | 190.26% | 686.22% |
| Total Current Liabilities | 4.9M | 1.67M | 1.26M | 897.99K | 2.97M | 4.13M | 23.59M | 31.27M | 21.03M | 28.15M |
| Accounts Payable | 3.04M | 1.67M | 1.26M | 897.99K | 2.72M | 0 | 4.83M | 6.24M | 8.18M | 2.72M |
| Days Payables Outstanding | - | - | - | 63.75 | - | - | 80.88 | 62.49 | 59.76 | 25.21 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 246.69K | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 1.37M | 0 | 0 | 0 | 0 | 0 | 17.98M | 0 | 0 | 36M |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 | 3.72M | 0 | 24.27M | 12M | 3.38M |
| Current Ratio | 3.70x | 9.40x | 6.75x | 11.74x | 11.33x | 8.82x | 1.82x | 1.63x | 7.77x | 7.77x |
| Quick Ratio | 3.70x | 9.40x | 6.75x | 11.74x | 11.33x | 8.82x | 1.82x | 1.63x | 7.77x | 7.77x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | 61.25 |
| Total Non-Current Liabilities | 17.86M | 3.38M | 3.38M | 3.38M | 3.45M | 5.83M | 14.72M | 4.86M | 3.99M | 14.42M |
| Long-Term Debt | 13.91M | 0 | 0 | 0 | 71.47K | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 2.45M | 1.88M | 1.49M | 616.32K | 15.64M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 3.95M | 3.38M | 3.38M | 3.38M | 3.38M | 3.38M | 3.38M | 3.38M | 3.38M | 6.75M |
| Total Liabilities | 22.75M | 5.05M | 4.63M | 4.27M | 6.42M | 9.96M | 38.31M | 36.13M | 25.02M | 42.57M |
| Total Debt | 13.91M | 0 | 0 | 0 | 318.16K | 2.87M | 2.56M | 2.24M | 1.45M | 14.54M |
| Net Debt | 10.7M | -6.14M | -4.26M | -3.9M | -32.35M | -32.01M | -7.04M | -12.46M | -9.84M | -4.97M |
| Debt / Equity | - | - | - | - | 0.01x | 0.09x | 0.22x | 0.10x | 0.01x | 0.01x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.17x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.06x |
| Interest Coverage | -49.26x | -32.25x | - | - | - | - | - | - | - | - |
| Total Equity | -4M▲ 0% | 11.23M▲ 380.5% | 4.62M▼ 58.9% | 6.84M▲ 48.2% | 28.2M▲ 312.3% | 31.37M▲ 11.2% | 11.79M▼ 62.4% | 22.6M▲ 91.8% | 145.46M▲ 543.6% | 83.87M▲ 0% |
| Equity Growth % | -287.99% | 380.45% | -58.89% | 48.18% | 312.31% | 11.23% | -62.43% | 91.76% | 543.6% | 1971.52% |
| Book Value per Share | -2.16 | 4.19 | 1.57 | 1.84 | 1.81 | 1.36 | 0.48 | 0.84 | 4.13 | 1.83 |
| Total Shareholders' Equity | -4M | 11.23M | 4.62M | 6.84M | 28.2M | 31.37M | 11.79M | 22.6M | 145.46M | 83.87M |
| Common Stock | 21.4K | 26.27K | 3.14K | 5.23K | 20.58K | 24.18K | 25.24K | 31.15K | 45.58K | 45.72K |
| Retained Earnings | -53.98M | -51.55M | -66.74M | -74.38M | -88.04M | -108.06M | -137.08M | -159.37M | -199.83M | -274.71M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 3.52K | 11.62K | 12.39K | -757 | 0 | 0 | 105.24K | 235.81K | 1.03M | 844.12K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CAPR Cash Flow Statement
Capricor Therapeutics, Inc. (CAPR) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -15.8M | -14.23M | -13.86M | -6.82M | -10.05M | -16.81M | 4.92M | -25.6M | -40M | -40M |
| Operating CF Margin % | -495.35% | -533.79% | -829.59% | -678.74% | -3240.87% | -6863.81% | 192.7% | -101.66% | -179.59% | - |
| Operating CF Growth % | -46.08% | 9.94% | 2.59% | 50.79% | -47.4% | -67.18% | 129.25% | -620.61% | -56.25% | -398.57% |
| Net Income | -18.81M | 2.43M | -15.19M | -7.64M | -13.66M | -20.02M | -29.02M | -22.29M | -40.47M | -81.99M |
| Depreciation & Amortization | 125.72K | 144.17K | 157.65K | 171.96K | 143.89K | 245.7K | 533.13K | 1.07M | 1.43M | 248M |
| Stock-Based Compensation | 1.96M | 1.71M | 1.73M | 700.98K | 1.95M | 2.97M | 4.46M | 7.39M | 9.77M | 7.38B |
| Deferred Taxes | -1.96M | 0 | 0 | 0 | -325.89K | -310.25K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 3.46M | -15.65M | 2.32M | 2.72K | 325.89K | 129.73K | 196.01K | -18.24K | 65.54K | -7.62B |
| Working Capital Changes | -583.03K | -2.86M | -554.59K | -55.34K | 1.51M | 182.34K | 28.75M | -11.75M | -10.78M | 2.9M |
| Change in Receivables | -11.4M | -121.24M | 139.71M | 116.9M | 87.97M | -391.75M | -155.83K | -9.82M | 3.5K | 350.17K |
| Change in Inventory | 11.6M | 121.36M | -139.79M | 156.28M | -1.91B | 391.75M | 0 | 0 | 0 | 0 |
| Change in Payables | 645.16K | -1.86M | -415.46K | -273.18M | 1.83B | 991.17K | 1.21M | 1.33M | 1.94M | 2.84M |
| Cash from Investing | -5.19M | 4.98M | 4.67M | -3M | 5.44M | -1.2M | -35.07M | 5.11M | -116.18M | -84.94M |
| Capital Expenditures | -193.74K | -32.19K | -316.49K | 0 | -547.6K | -1.2M | -3.36M | -2.05M | -1.54M | -3.32M |
| CapEx % of Revenue | 6.07% | 1.21% | 18.94% | - | 176.5% | 488.48% | 131.68% | 8.13% | 6.91% | - |
| Acquisitions | 1.77M | 0 | 0 | 0 | -5.99M | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -1.77M | 5.01M | 4.99M | 0 | 5.99M | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 18.63M | 11.58M | 6.85M | 9.18M | 33.38M | 20.23M | 4.87M | 25.58M | 152.77M | 81.16M |
| Debt Issued (Net) | 4.75M | 500K | 0 | 0 | 318.16K | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1.07M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | -193 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 13.97K | 6.64K | 139.14K | 3.22K | 5.72M | 50.56K | 70.3K | 64.6K | 450.17K | 247.96K |
| Net Change in Cash | -2.36M▲ 0% | 2.33M▲ 198.6% | -2.34M▼ 200.3% | -645.77K▲ 72.4% | 28.77M▲ 4554.6% | 2.22M▼ 92.3% | -25.28M▼ 1239.1% | 5.09M▲ 120.1% | -3.41M▼ 166.9% | -45.14M▲ 0% |
| Free Cash Flow | -16M▲ 0% | -14.26M▲ 10.8% | -14.18M▲ 0.6% | -6.82M▲ 51.9% | -10.6M▼ 55.4% | -18.01M▼ 69.8% | 1.56M▲ 108.6% | -27.64M▼ 1875.6% | -41.53M▼ 50.2% | -44.68M▲ 0% |
| FCF Margin % | -501.42% | -535% | -848.53% | -678.74% | -3417.38% | -7352.29% | 61.02% | -109.79% | -186.5% | -401.39% |
| FCF Growth % | -45.83% | 10.83% | 0.59% | 51.89% | -55.43% | -69.83% | 108.65% | -1875.58% | -50.25% | -16.57% |
| FCF per Share | -8.62 | -5.32 | -4.82 | -1.84 | -0.68 | -0.78 | 0.06 | -1.03 | -1.18 | -1.18 |
| FCF Conversion (FCF/Net Income) | 0.84x | -5.85x | 0.91x | 0.89x | 0.74x | 0.84x | -0.17x | 1.15x | 0.99x | 0.54x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CAPR Key Ratios
Capricor Therapeutics, Inc. (CAPR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | 67.31% | -191.78% | -133.42% | -77.95% | -67.23% | -134.49% | -129.63% | -48.16% | -97.76% |
| Return on Invested Capital (ROIC) | -275.18% | -163.71% | -422.38% | -351.93% | - | - | -1087.55% | -242.63% | -43.8% | -43.8% |
| Gross Margin | -377.52% | 100% | 100% | -411.61% | 100% | 100% | -755.07% | -44.76% | -124.37% | -581.7% |
| Net Margin | -589.56% | 91.19% | -909.1% | -760.36% | -4401.94% | -8175.86% | -1137.37% | -88.52% | -181.71% | -736.62% |
| Debt / Equity | - | - | - | - | 0.01x | 0.09x | 0.22x | 0.10x | 0.01x | 0.01x |
| Interest Coverage | -49.26x | -32.25x | - | - | - | - | - | - | - | - |
| FCF Conversion | 0.84x | -5.85x | 0.91x | 0.89x | 0.74x | 0.84x | -0.17x | 1.15x | 0.99x | 0.54x |
| Revenue Growth | -15.52% | -16.43% | -37.32% | -39.85% | -69.13% | -21.06% | 941.85% | 886.81% | -11.55% | -52.08% |
CAPR SEC Filings & Documents
Capricor Therapeutics, Inc. (CAPR) SEC filings — annual & quarterly reports (10-K, 10-Q)
CAPR Frequently Asked Questions
Capricor Therapeutics, Inc. (CAPR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Capricor Therapeutics, Inc. (CAPR) reported $11.1M in revenue for fiscal year 2024.
Capricor Therapeutics, Inc. (CAPR) saw revenue decline by 11.5% over the past year.
Capricor Therapeutics, Inc. (CAPR) reported a net loss of $82.0M for fiscal year 2024.
Dividend & Returns
Capricor Therapeutics, Inc. (CAPR) has a return on equity (ROE) of -48.2%. Negative ROE indicates the company is unprofitable.
Capricor Therapeutics, Inc. (CAPR) had negative free cash flow of $44.7M in fiscal year 2024, likely due to heavy capital investments.
Explore More CAPR
Capricor Therapeutics, Inc. (CAPR) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates